The patent application WO2018117152, which relates to delgocitinib, can be found through Google Patents [1]. Delgocitinib is a Janus kinase (JAK) inhibitor [2].
What is Delgocitinib Used For?
Delgocitinib is being developed for the treatment of atopic dermatitis and is a topical JAK inhibitor [2]. It is also being investigated for other inflammatory conditions [3].
How Does Delgocitinib Work?
Delgocitinib inhibits Janus kinases (JAKs), which are intracellular enzymes involved in signaling pathways that mediate inflammation [2]. By blocking these pathways, delgocitinib aims to reduce the inflammation associated with conditions like atopic dermatitis [2][3].
What is the Patent Status of Delgocitinib?
Information on the specific patent status, including expiry dates and any challenges, for delgocitinib can be accessed through resources like DrugPatentWatch.com [1]. Patent applications like WO2018117152 describe potential new uses or formulations of existing drugs [1].
Who is Developing Delgocitinib?
Pharmaceutical companies like Anacor Pharmaceuticals, which was acquired by Pfizer, and later Torii Pharmaceutical Co., Ltd. have been involved in the development of delgocitinib [2][3].
What are the Clinical Trial Results for Delgocitinib?
Clinical trials have shown that topical delgocitinib can effectively reduce symptoms of atopic dermatitis, such as itch and skin lesions [2][3]. Further data on its efficacy and safety profiles is available through clinical trial databases and pharmaceutical company reports.
What are Other Treatments for Atopic Dermatitis?
Current treatments for atopic dermatitis include topical corticosteroids, topical calcineurin inhibitors, and systemic immunosuppressants. Delgocitinib represents a novel topical JAK inhibitor in this therapeutic area [2].
Sources
1. https://patents.google.com/patent/WO2018117152A1/en
2. https://drugpatentwatch.com/delgocitinib
3. https://www.torii-pharm.co.jp/en/